Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sars vaccines and methods to produce highly potent antibodies

A technology of vaccines and antibodies, which is applied in the fields of preparation methods of peptides, chemical instruments and methods, medical preparations containing active ingredients, etc., and can solve problems such as unclear efficacy

Inactive Publication Date: 2008-01-02
NEW YORK BLOOD CENT
View PDF2 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the inactivated SARS-CoV has been shown to be effective in protecting animals from SARS-CoV challenge, its efficacy in humans is unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sars vaccines and methods to produce highly potent antibodies
  • Sars vaccines and methods to produce highly potent antibodies
  • Sars vaccines and methods to produce highly potent antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0030] The present invention provides a vaccine comprising an effective amount of isolated polypeptides and recombinant proteins containing the receptor binding domain (RBD) of SARS-associated coronavirus spike protein or its function fragment. In one embodiment, suitable adjuvants are used with the vaccines described herein. In another embodiment, the vaccine is conjugated.

[0031] As used herein, a functional fragment is the portion of the RBD that performs the described function. In one embodiment, the function is to bind a receptor.

[0032] Peptide or polypeptide or protein with RBD sequence

[0033] The present invention provides an isolated peptide or polypeptide or protein comprising a receptor binding domain sequence or a functional fragment thereof in the spike protein of severe acute respiratory syndrome-associated coronavirus, which can be used for preventing severe acute respiratory syndrome-associated coronavirus Vaccine for coronavirus infection.

[0034] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention provides a vaccine comprising an effective amount of an isolated polypeptide or recombinant protein containing the sequence of the receptor-binding domain in the SARS associated coronavirus spike protein or a functional fragment thereof, or a nucleic acid molecule comprising the sequence of a fragment which encodes the sequence of the receptor-binding domain in the Severe Acute Respiratory Syndrome associated coronavirus spike protein or a functional fragment thereof. This invention provides a composition for increasing the immunogenicity of an antigen comprising an effective amount of an antigen and an IgG Fc domain, its functional fragment, or a substance containing an IgG Fc domain or its functional fragment. The antigen and the IgG Fc may be linked or unlinked. Finally, this invention also provides method for using any of the above compositions for immunization.

Description

[0001] This application claims priority to applications filed May 31, 2005, which have not yet received a U.S. serial number, and U.S. Serial No. 60 / 576,118, filed June 2, 2004, both of which are incorporated in their entirety by this application middle. [0002] This application cites a number of publications. The entire contents of these publications are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. Background of the invention [0003] Severe acute respiratory syndrome (SARS), an emerging infectious disease caused by SARS-related coronavirus (SARS-CoV) [1-7], may have originated from some wild animals [8]. The global outbreak of SARS in 2002 / 2003 resulted in thousands of cases and hundreds of deaths, seriously threatening public health worldwide. In late 2003 and early 2004, several new SARS-CoV infections were reported in China with strains different from those responsible for ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/215C07K1/00
Inventor 姜世勃何玉先刘叔文
Owner NEW YORK BLOOD CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com